ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children with Achondroplasia followed by an Open Label Extension period

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515469-32-00

Acronym

ASND0036

Enrollment

Registered

2024-09-26

Start date

2023-03-02

Completion date

2025-08-13

Last updated

2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achondroplasia in Children and Adolescents

Brief summary

Annualized growth velocity (AGV) at Week 52

Detailed description

Change from baseline in height Z-score at Week 52

Interventions

DRUGTransCon CNP

DRUGPlacebo for TransCon CNP

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Annualized growth velocity (AGV) at Week 52	—

Secondary

Measure	Time frame
Change from baseline in height Z-score at Week 52	—

Countries

Denmark, Ireland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026